In the world of medical research, sometimes the most anticipated findings can lead to surprising conclusions. Such is the case with the recent UK-led clinical trial that examined the use of surfactant for infants with severe bronchiolitis. This study, funded by a partnership between the UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR), along with Chiesi Farmaceutici SpA, Italy, aimed to determine whether a treatment commonly used for premature babies could also benefit those on life support with this seasonal viral illness. However, the results, published in The Lancet Respiratory Medicine, revealed that surfactant offers no advantage for infants with severe bronchiolitis, despite its routine use in premature infants. This finding raises important questions about the treatment's efficacy and the need for further research into targeted therapies for bronchiolitis.
Bronchiolitis, most often caused by the respiratory syncytial virus (RSV), is a leading reason for hospital admissions in the UK during winter. It typically affects babies under one year old, with those born prematurely being particularly vulnerable. While most babies admitted will recover with oxygen and fluids, around a thousand require intensive care and a ventilator to support their breathing. Currently, there is no specific treatment for RSV infection, but a vaccine is now being offered to pregnant women in the last months of pregnancy, which will protect their newborn babies from severe bronchiolitis.
The Bronchiolitis Endotracheal Surfactant Study (BESS) trial, the largest-ever randomized study of surfactant for bronchiolitis, involved 232 critically ill babies across 15 children's hospitals in England, Scotland, and Northern Ireland. The study's lead, Professor Calum Semple OBE from the University of Liverpool and Alder Hey Children's NHS Foundation Trust, expressed disappointment that the treatment did not make a difference in how long babies stayed on ventilators. While the treatment was safe, it failed to speed up recovery for these very sick babies, according to Professor Semple.
This finding is particularly intriguing, as surfactant is routinely used to help premature infants breathe more easily. The study team had hoped that this therapy could also benefit babies hospitalised with bronchiolitis, but the evidence does not support this. This raises a deeper question: if surfactant is not effective for bronchiolitis, what other treatments could be explored to improve outcomes for these vulnerable infants?
One thing that immediately stands out is the need for further research into targeted treatments for bronchiolitis. While surfactant therapy remains essential for premature newborn babies, the BESS trial suggests that it may not be the best approach for infants with severe bronchiolitis. This opens up a new avenue for exploration, with researchers advocating for studies that could lead to more effective and tailored therapies for this condition.
In my opinion, this study highlights the importance of rigorous clinical trials in evaluating the efficacy of medical treatments. While surfactant is a well-established therapy for premature infants, its application to bronchiolitis requires further investigation. The BESS trial serves as a reminder that what works for one condition may not necessarily work for another, and that a one-size-fits-all approach to treatment can be misleading. Instead, we must embrace a more nuanced understanding of disease pathophysiology and develop targeted therapies that address the specific needs of each patient.
From my perspective, this study also underscores the critical role of vaccines in preventing severe bronchiolitis. The offer of the RSV vaccine during pregnancy is a promising development, as it provides a simple and effective way to protect newborn babies from this serious illness. While further research is needed to optimise the vaccine's efficacy and ensure widespread adoption, this study serves as a reminder of the potential for preventive measures to significantly reduce the burden of bronchiolitis.
In conclusion, the BESS trial's findings are a wake-up call for the medical community to re-evaluate the use of surfactant for bronchiolitis and explore alternative treatments. While the study did not find a benefit for surfactant, it opens up new avenues for research and highlights the need for a more targeted approach to therapy. As we continue to search for better ways to care for these sick babies, I urge researchers to embrace a more nuanced understanding of disease pathophysiology and develop treatments that are tailored to the specific needs of each patient.
